Eikon Therapeutics, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Eikon Therapeutics (EIKN) presented at the Cantor Fitzgerald conference, highlighting its oncology pipeline, including PARP1 inhibitors and TLR7/8 programs. The company reported $531.2M in cash and a $75M quarterly burn rate. Key data for its lead programs is expected in early 2027. Management also discussed expansion into neuroscience, inflammatory disease, and cardiovascular research.
Column Group IV GP, LP purchased 89,200 indirectly-held shares of Eikon Therapeutics, Inc. (EIKN) at $11.56 ($1.03M total) on 2026-09-03. Filed jointly with Column Group IV-A, LP (10% owner), Column Group IV, LP (10% owner), Column Group Opportunity III, LP (10% owner), Column Group Opportunity III GP, LP (10% owner), TCG Opportunity III GP, LLC (10% owner), Kutzkey Tim (10% owner) and Svennilson Peter (10% owner).
Latigo Biotherapeutics and Eikon Therapeutics appointed new executives following their IPOs. Allogene Therapeutics and LB Pharma also announced leadership changes, reflecting broader biotech sector restructuring. These moves are part of organizational development in the public market.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning EIKN (Eikon Therapeutics, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent EIKN coverage spans technology, financial news and insider activity.
In the last 30 days, EIKN insiders filed 1 SEC Form 4 transaction — 1 purchase ($1.0M) and no sales. The most active reporter was Column Group IV GP, LP with 1 filing.
The company’s strong cash runway and upcoming Phase II/III readouts could support a near‑term share price rally if data are positive.
Small insider purchase may signal confidence but limited price impact.
New leadership could influence strategic direction but no immediate catalyst.
New CSO may strengthen pipeline execution and affect stock perception.
Positive early efficacy and safety signals may boost investor sentiment, but data are preliminary.
AlphAI scores every news story that mentions EIKN with an AI model for sentiment and relevance, and aggregates insider trades from Eikon Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Eikon Therapeutics (EIKN) presented at the Cantor Fitzgerald conference, highlighting its oncology pipeline, including PARP1 inhibitors and TLR7/8 programs. The company reported $531.2M in cash and a $75M quarterly burn rate. Key data for its lead programs is expected in early 2027. Management also discussed expansion into neuroscience, inflammatory disease, and cardiovascular research.
3 min readColumn Group IV GP, LP purchased 89,200 indirectly-held shares of Eikon Therapeutics, Inc. (EIKN) at $11.56 ($1.03M total) on 2026-09-03. Filed jointly with Column Group IV-A, LP (10% owner), Column Group IV, LP (10% owner), Column Group Opportunity III, LP (10% owner), Column Group Opportunity III GP, LP (10% owner), TCG Opportunity III GP, LLC (10% owner), Kutzkey Tim (10% owner) and Svennilson Peter (10% owner).
1 min readLatigo Biotherapeutics and Eikon Therapeutics appointed new executives following their IPOs. Allogene Therapeutics and LB Pharma also announced leadership changes, reflecting broader biotech sector restructuring. These moves are part of organizational development in the public market.
2 min readEikon Therapeutics (EIKN) appointed Dr. Ching-Pin Chang as Executive VP & Chief Scientific Officer. Chang has extensive experience in cardiovascular research and drug discovery. The company focuses on oncology with several clinical-stage drug candidates. EIKN shares are down 1.49% at $11.21.
2 min readEikon Therapeutics (NASDAQ:EIKN) is developing PARP1 inhibitors EIK1003 and EIK1004, targeting cancer treatments. EIK1003 is being tested in combinations with paclitaxel, carboplatin, and abiraterone. EIK1004 is designed for brain penetration. The company also has EIK1005, a Werner helicase inhibitor, in early studies. Eikon aims to address unmet medical needs in oncology.
2 min readEikon Therapeutics filed an 8-K to provide an updated corporate presentation and clinical updates. For EIK1001 (TLR7/8) TeLuRide-005, fully enrolled, NSCLC ORR was 63.1% with median DOR over 11 months as of May 4, 2026, and Grade ≥3 drug-related TRAEs were 48.6%. EIK1003 showed ORR 14.3% (monotherapy) and 24.5% (combo).
1 min readEikon Therapeutics, Inc. (EIKN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates • Eikon announced seven abstracts accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026 highlighting progress across Eikon’s oncology
5 min readEikon Therapeutics (Nasdaq: EIKN) said its independent Data Monitoring Committee recommended continuing the TeLuRide-006 adaptive Phase 2/3 trial of EIK1001 in advanced melanoma and selecting 0.60 mg/m2 as the single dose for patients randomized to EIK1001. The dose follows a prespecified analysis of unblinded data.
4 min readEikon Therapeutics (Nasdaq: EIKN) said it added Johnny Bennett, Ph.D. to its Scientific Advisory Board. Bennett is Vice President and Head of Discovery Chemistry at Merck Research Laboratories. Eikon noted Merck has supplied KEYTRUDA (pembrolizumab) for registration-enabling trials for EIK1001 and supported early combinations with EIK1005, and participated in Eikon’s IPO.
2 min readEikon Therapeutics, Inc. (EIKN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective July 31, 2026, Leon Chen, Ph.D. and Joshua Wolfe resigned from the Board of Directors of Eikon Therapeutics, Inc.
2 min read
